Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-05-15
2007-05-15
Tsang, Cecilia J. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000, C530S381000, C530S412000
Reexamination Certificate
active
10817248
ABSTRACT:
The present invention provides compounds that inhibit Factor XIa and methods of preventing or treating undesired thrombosis by administering a compound of the invention to a mammal. The invention also provides three-dimensional structures of Factor XIa and methods for designing or selecting additional Factor XIa inhibitors using these structures.
REFERENCES:
patent: 4461724 (1984-07-01), Konishi
patent: 4904659 (1990-02-01), Atwell et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5658902 (1997-08-01), Ahn et al.
patent: 5919589 (1999-07-01), Kawakami et al.
patent: 5942620 (1999-08-01), Krantz et al.
patent: 6048720 (2000-04-01), Dalborg et al.
patent: 6258822 (2001-07-01), Geyer et al.
patent: 6284796 (2001-09-01), Geyer et al.
patent: 6608026 (2003-08-01), Wang et al.
patent: 2005/0143317 (2005-06-01), Abdel-Meguid et al.
patent: 0206802 (1993-09-01), None
patent: WO 96/18644 (1996-06-01), None
patent: WO 00/32590 (2000-06-01), None
patent: WO 00/66545 (2000-11-01), None
patent: WO 00/69832 (2000-11-01), None
patent: WO 02/24667 (2002-03-01), None
M.-F. Sun, et al. J. Biol. Chem. (1999), 274(51), pp. 36373-36378.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
H.J.C. Berendsen. A Glimpse of the Holy Grail? Science (1998) 282, pp. 642-643.
D. Voet and J.G. Voet. Biochemistry, 2nd Edition.(1995), pp. 235-241.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
Y. Inada, et al. Methods Enzymol. (1994) 242, pp. 65-90.
H.F. Gaertner and R.E. Offord. Bioconj. Chem. (1996) 7(1), pp. 38-44.
T.M. Penning, et al. J. Biol. Chem. (1982) 257(21), pp. 12589-12593.
J.L. Strominger, et al. J. Am. Chem. Soc. (1959), 81, pp. 3803-3804.
Granberg et al., X-ray crystallographic studies of des-Gla-FVIIa/sTF complexes and their use in structure based design. Poster MEDI 85 American Chemical Society 226thNational Meeting, Sep. 8, 2003.
Holmes et al., “Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration,”Bioconjug. Chem.11(4):439-444 (2000).
Johansson-Zetterberg et al., Search for bensamidine P1-replacement in FVIIa dipeptide Inhibitors. Poster MEDI 83 American Chemical Society 226thNational Meeting, Sep. 8, 2003.
Klinghofer et al., “Species specificity of amidine-based urokinase inhibitors,”Biochemistry40(31):9125-9131 (2001).
Meijers et al., “High levels of coagulation factor XI as a risk factor for venous thrombosis,”N. Engl. J. Med.342(10):696-701 (2000).
Outt et al., “A General Synthesis of 4-Substituted 6-(2-Imidazolinylamino)-5,8-dimethylquinolines,”J. Org. Chem.63(17):5762-5768 (1998).
Parlow et al., “Polymer-assisted solution-phase library synthesis and crystal structure of alpha-ketothiazoles as tissue factor VIIa inhibitors,”J. Med. Chem.46(19):4043-4049 (2003).
Veale et al., “Nonpeptidic inhibitors of human leukocyte elastase.5.Design, synthesis, and X-ray crystallography of a series of orally active 5-aminopyrimidin-6-one-containing trifluoromethyl ketones,”J. Med. Chem.38(1):98-108 (1995).
Baird and Walsh, “The Interaction of Factor XIa with Activated Platelets but Not Endothelial Cells Promotes the Activation of Factor IX in the Consolidation Phase of Blood Coagulation,”The Journal of Biological Chemistry277:38462-38467 (2002).
Minnema et al., “Activation of Clotting Factor XI Without Detectable Contact Activation in Experimental Human Endotoxemia,”Blood92:3284-3301 (1998).
Salomon et al., “Prevalence, Causes, and Characterization of Factor XI Inhibitors in Patients with Inherited Factor XI Deficiency,”Blood101:4783-4788 (2003).
Zivelin et al., “Factor XI Deficiency in French Basques is Caused Predominantly by an Ancestral Cys38Arg Mutation in the Factor XI Gene,”Blood99:2448-2454 (2002).
Information, Applicant's Statement, Jun. 2006.
Abdel-Meguid Sherin S.
Babine Robert E.
Bannister Thomas D.
Deng Hongfeng
Gho Zihong
Clark Paul T.
Clark & Elbing LLP
Daiamed, Inc.
Kosar Andrew D.
Tsang Cecilia J.
LandOfFree
Compounds and methods for treatment of thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treatment of thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treatment of thrombosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3813719